Loading…
ELUT
Elutia Inc
NASDAQ· Healthcare· Medical Devices· CUSIP 05479K106
$0.880.00%Price as of Aug 29, 18:42 UTC · updated once a day, after the close
Key metrics
- Market cap
- $38.97M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.59
- ROE
- —
- Profit margin
- 426.89%
- Revenue growth
- -11.60%
- Beta
- 0.88
- 52-week high
- $2.38
- 52-week low
- $0.50
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -85.9% over 5Y.
today you would have $117.87▼ -88.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $0.69 | $3.74 | $2.16 | $4.25 | $6.30 | $13.63 | |
| P/E | — | 0.8x | — | — | — | — | — |
| P/S | 2.0x | 2.6x | 7.5x | 1.6x | 2.5x | 1.4x | 0.9x |
| P/B | 1.9x | 1.2x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CPHIChina Pharma Holdings Inc | $0.90 | — | 1.0x | — | -20.99% | $38.9M |
| CRVOCervoMed Inc. | $2.60 | — | 1.5x | — | -107.62% | $39.31M |
| DCGODocGo Inc. | $0.40 | — | 0.3x | — | -107.79% | $39.32M |
| PAVMPAVmed Inc. | $4.92 |
About the company
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
- 25
- Gaithersburg, United States
Company description provided by Yahoo Finance.